Comment on “Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives” by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv. , 2025, 15 , 231–243
RSC Advances · 2025 · 15 (52) · 44437-44438
DOI: 10.1039/d5ra00388a ↗Kurz gefasst
Kommentar in der Zeitschrift RSC Advances, 2025. Verfasst von Ralf Weiskirchen. Beteiligte Einrichtung: Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH Aachen University Hospital Aachen Germany…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
This comment critically evaluates a study by Lu and colleagues, highlighting the misidentification and HeLa cell contamination in the three cell lines used to evaluate the anticancer properties of quinoline-based dihydrazone derivatives.
Autor:innen und Institutionen
- Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH Aachen University Hospital Aachen Germany rweiskirchen@ukaachen.de +49-(0)241-8088683.
ORCID-Profile: Ralf Weiskirchen
Zitieren
APA
Weiskirchen, R. (2025). Comment on “Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives” by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv. , 2025, 15 , 231–243. RSC Advances, 15(52), 44437-44438. https://doi.org/10.1039/d5ra00388a
Vancouver
Weiskirchen R. Comment on “Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives” by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv. , 2025, 15 , 231–243. RSC Advances. 2025;15(52):44437-44438. doi:10.1039/d5ra00388a
BibTeX
@article{Weiskirchen2025,
author = {Weiskirchen, Ralf},
title = {Comment on “Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives” by J.-X. Lu, H.-R. Lan, D. Zeng, J.-Y. Song, Y.-T. Hao, A.-P. Xing, A. Shen, and J. Yuan, RSC Adv. , 2025, 15 , 231–243},
journal = {RSC Advances},
year = {2025},
volume = {15},
number = {52},
pages = {44437--44438},
doi = {10.1039/d5ra00388a}
}
EUVIMED